TRPV1 Agonist Therapy for Stabilizing Blood Pressure in Septic Shock

OVERVIEW

This invention presents a novel treatment for stabilizing blood pressure in septic shock using TRPV1 agonists. Unlike current therapies, TRPV1 agonists maintain blood pressure without compromising blood flow to critical organs like the spleen, kidney, and liver. This solution provides a safer and more effective alternative to existing vasoconstrictors, which often impair organ perfusion. TRPV1 agonists, including capsaicin and vanillotoxin derivatives, can be formulated for parenteral administration, ensuring rapid and sustained blood pressure stabilization during septic shock.

BACKGROUND

Severe sepsis is a leading cause of death in ICU patients, with high mortality rates and significant healthcare costs. Current treatments like adrenergic agonists and angiotensin II have limited efficacy and can compromise vital organ perfusion. This invention addresses these challenges by using TRPV1 agonists, which safely increase blood pressure while preserving organ function, offering a superior alternative for managing septic shock.

Benefit

• Organ-Safe: Maintains blood pressure without compromising perfusion to the spleen, kidney, and liver.
• Effective: Provides a more reliable increase in blood pressure compared to current treatments.
• Rapid Administration: Designed for quick, parenteral delivery in emergency scenarios.
• Reduced Side Effects: Avoids the pro-coagulant and adverse thromboembolic events seen with angiotensin II.
• Cost-Effective: Potentially lowers healthcare costs associated with septic shock treatment.

Market Application

• Septic Shock: Treatment for stabilizing blood pressure in patients with severe sepsis.
• Distributive Shock: Applicable for other types of shock where blood pressure support is needed.
• Critical Care: Use in ICU settings to manage hypotensive patients effectively.
• Emergency Medicine: Rapid intervention in emergency departments for shock stabilization.

Publications

• US National Phase Patent Application for TRPV1 Agonists in Septic Shock Treatment.
• "Angiotensin II for the Treatment of Vasodilatory Shock," NEJM 377 (2017) 419-430.
• "The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)," JAMA 315(8) (2016) 801-810.